About Moximed
Moximed is a Healthcare company based in Hayward (United States) founded in 2006 by Josh Makower and Anton Clifford. A knee implant for pre-arthroplasty osteoarthritis patients is developed. Moximed has raised $262.34 million across 8 funding rounds from investors including Runway Growth Capital, Advent Life Sciences and GBS. Its chief executive, as recorded, is Christopher Gleason. Moximed offers products and services including MISHA Knee System. Its focus areas include Life Sciences, Orthopedics, Medical Devices and Therapies. Its legal entity is MOXIMED INC. Its competitors include Allay Therapeutics, Sparta Biomedical and Optimotion Implants; 3 of its 3 listed competitors have raised funding.
Company details
Moximed was founded in 2006 and is headquartered in Hayward, United States. Medical devices for orthopedic applications are developed, with a focus on knee osteoarthritis treatments. The KineSpring Knee Implant System is provided as the primary product, functioning as a partial load absorber that reduces knee joint pressure by up to 13 kg for eligible patients prior to full joint replacement. Operations center on implant innovation in the medtech sector.
- Headquarters Hayward, United States
- Founders Josh Makower, Anton Clifford
- SectorsHealthcare
- Website moximed.com
- Social LinkedIn X YouTube
- Legal Name Moximed Inc.
- Total Equity Funding$262.34M (USD)
in 8 rounds
- Latest Funding Round$62.71M (USD), Series D
Aug 2024
- InvestorsRunway Growth Capital
& 11 more
Products & Services of Moximed
Moximed offers a comprehensive portfolio of products and services, including MISHA Knee System.
Implantable shock absorber for relieving knee osteoarthritis pain and improving mobility.
Apps and channels of Moximed
its YouTube channel Moximed has 323 subscribers and 12 videos.
Videos from Moximed
The most watched videos on Moximed's YouTube channel, Moximed (323 subscribers). Click a video to play it here.
More on Moximed.
Funding Insights of Moximed
Moximed has successfully raised a total of $262.34M across 8 strategic funding rounds. The most recent funding activity was a Series D round of $62.71 million completed in August 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $262.34M
- Total Rounds 8
- Last Round Series D — $62.71M
- First Round $20.79M
(Jun 2008)
- Investors Count 12
All 8 funding rounds of Moximed with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug 2024 | $62.71M | Series D | – | Elevage Medical Technologies | |
| Aug 2022 | Debt – Conventional | – | – | ||
| Aug 2022 | $40M | Series C | – | Vertex Ventures HC | |
| Mar 2017 | $50M | Series C | – | Advent Life Sciences, Future Fund | |
| May 2015 | $33M | Series C | – | Vertex Ventures | |
| Dec 2011 | $45.84M | Series C | – | Gilde Healthcare | |
| Aug 2009 | $10M | Series B | – | – | – |
| Jun 2008 | $20.79M | Series B | – | – | – |
12 investors in total: 12 institutional.
Investors in Moximed
Moximed has secured backing from 12 investors, including venture fund and institutional investors. Prominent investors backing the company include Runway Growth Capital, Advent Life Sciences and GBS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Early and mid-stage life science focused VC firm investing in the US and Europe | adventls.com | London, United Kingdom | ||
| gbsventures.com.au | ||||
Private equity and venture captial firm focused on healthcare sectors | gildehealthcare.com | Cambridge, United States | ||
Venture capital and private equity investment firm | morgenthaler.com | Portola Valley, United States | ||
Venture capital investments are offered to startups by NEA. | nea.com | Menlo Park, United States | ||
| vertexventureshc.com | ||||
| warrenpointcapital.com | ||||
Support is provided to growth-stage medical technology companies. | elevagemedical.com | Austin, United States | ||
Venture debt financing is provided to companies across multiple sectors. | 2015 | runwaygrowth.com | Woodside, United States | |
Sovereign Wealth Fund of Government of Australia | futurefund.gov.au | Melbourne, Australia |
Investor details for Moximed
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Moximed
23 people are tracked at Moximed (11 in leadership, 7 in board & advisors, 5 in team).
| Name | Role | Group |
|---|---|---|
Josh Makower | Co-Founder | Leadership |
Anton Clifford | Co-Founder & CTO | Leadership |
Christopher Gleason | CEO | Leadership |
Christine Barcelos | VP, Corporate Operations | Leadership |
Keith Fong | VP, Marketing & Business Development | Leadership |
Debra Snowdale | CFO | Leadership |
John Barter | Business Development Director Northern Europe & South Africa | Leadership |
Brian Donovan | Chief Operating Officer | Leadership |
David Lowe | Director Of R&D | Leadership |
Paul O Connor | Director of Operations | Leadership |
Jeremy Lane | Sr. Director Of Information Technology | Leadership |
Brigitte Smith | Director | Board & advisors |
Joshua Makower | Chairman | Board & advisors |
Arthur Franken | Director | Board & advisors |
Shahzad Malik | Director | Board & advisors |
Hank Plain | Director | Board & advisors |
Kevin Sidow | Director | Board & advisors |
Yoh-Chie Lu | Director | Board & advisors |
Wendy Sawyer | SVP Operations & Product Development | Team |
Ted Lamson | Commercial Council Member | Team |
3 more people are available in the full profile.
Complete people profiles for Moximed
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Moximed
3 dated milestones of Moximed across 18 years, from founding to its latest funding, stage changes and deals.
- Founded Moximed is founded.
- Funding First funding round of $20.8M.
- Funding Latest funding round, Series D, of $62.7M.
Competitors of Moximed
Moximed has 3 listed competitors in our database, 3 of them funded. They include Allay Therapeutics, Sparta Biomedical and Optimotion Implants.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| allaytx.com | 2017 | Menlo Park, United States | $146.89M | Post-surgical pain drugs are developed using non-opioid biopolymer technology. | ||
| spartabiomedical.com | 2017 | Research Triangle Park, United States | $5M | Synthetic cartilage platforms are developed for orthopedic surgeons. | ||
| optimotionimplants.com | 2016 | Orlando, United States | $2.25M | Knee replacement implants and surgical devices are developed. |
Detailed competitors of Moximed
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Moximed
The website of Moximed (moximed.com) receives about 3.3K visits a month.
- Monthly visits3.3K
▼ 51% vs previous month
Top companies in Orthopedics
3 companies that operate in the same segment as Moximed (Orthopedics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Provider of high-frequency spinal cord stimulation implants | 2006 | Menlo Park, California, United States | USD 154.1 M | USD 353.08 M | 1,215 | |
Developer of therapies for the treatment of musculoskeletal disorders | 2007 | Woburn, Massachusetts, United States | USD 62 M | USD 85.55 M | 692 | |
Antibody-siRNA complexes are developed for cancer treatment. | 2012 | San Diego, California, United States | USD 142.54 M | USD 10.9 M | 391 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Moximed
Complete news archive for Moximed
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Moximed
Moximed was founded in 2006 and raised its 1st funding round 2 years after it was founded.
Moximed is headquartered in Hayward, United States. It is registered at Hayward, California, United States.
Christopher Gleason is the CEO of Moximed, as recorded in our data.
Moximed is a funded company, having raised a total of $262.34M across 8 funding rounds to date. The company's 1st funding round was a Series B of $20.79M, raised on Jun 2008.
Moximed was founded in 2006 and is headquartered in Hayward, United States. Medical devices for orthopedic applications are developed, with a focus on knee osteoarthritis treatments. The KineSpring Knee Implant System is provided as the primary product, functioning as a partial load absorber that reduces knee joint pressure by up to 13 kg for eligible patients prior to full joint replacement. Operations center on implant innovation in the medtech sector.
Moximed's top competitors include Allay Therapeutics, Sparta Biomedical and Optimotion Implants.
Moximed offers MISHA Knee System.
Moximed has 12 investors. Key investors include Runway Growth Capital, Advent Life Sciences, GBS, Gilde Healthcare, and Morgenthaler.
Moximed operates through Moximed Inc..